greeksoup/ stock research
Stock research / United States / Funds / Ra Capital Management, L.P.

Ra Capital Management, L.P.

CIK 1346824 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Ra Capital Management, L.P. reported 84 US-listed holdings worth $11.51 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Ascendis Pharma A/s (23.8%), Parabilis Medicines Inc. Com (6.9%) and Rhythm Pharmaceuticals Inc. (6.4%). Against the quarter before, it opened 17 positions, added to 9, trimmed 10 and sold out of 18.

Reported holdings$11.51B+21.9% on Q1 2026
Positions84-1 on Q1 2026
The largest ten60.4%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedHeldTrimmed
ASND23.8%PBLS6.9%RYTM6.4%PCVX5.8%SION3.8%TYRA3.4%EWTX3.0%NAMS2.8%COAG2.5%SEPN2.0%BCAX1.9%MLYS1.8%GHRS1.8%70 more32.6%

The 14 largest of its 84 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $8.67 billion in 81 positions$8.67BQ3 24Q4 2024: $7.51 billion in 89 positions$7.51BQ4 24Q1 2025: $5.99 billion in 85 positions$5.99BQ1 25Q2 2025: $5.94 billion in 63 positions$5.94BQ2 25Q3 2025: $8.12 billion in 67 positions$8.12BQ3 25Q4 2025: $9.76 billion in 71 positions$9.76BQ4 25Q1 2026: $9.44 billion in 85 positions$9.44BQ1 26Q2 2026: $11.51 billion in 84 positions$11.5BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 17Added 9Held 48Trimmed 10Sold out 18
Opened: 17Added: 9Held: 48Trimmed: 10Sold out: 18

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 17

  1. Ascendis Pharma A/s ASND$2.74 billion
  2. Parabilis Medicines Inc. Com PBLS$791.9 million
  3. Hemab Therapeutics Hldgs Inc. COAG$286.8 million
  4. Abivax SA ABVX$150.9 million
  5. Oruka Therapeutics Inc. ORKA$148.0 million
  6. Intellia Therapeutics Inc. NTLA$76.6 million
  7. Definium Therapeutics Inc. DFTX$70.6 million
  8. Sana Biotechnology Inc. SANA$65.4 million

and 9 more in the table below

Added to 9

  1. Artiva Biotherapeutics Inc. ARTV+8.1 million shares · +82%
  2. Aclaris Therapeutics Inc. ACRS+5.9 million shares · +87%
  3. Solid Biosciences Inc. SLDB+2.7 million shares · +29%
  4. Acrivon Therapeutics Inc. ACRV+3.9 million shares · +47%
  5. Avalo Therapeutics Inc. AVTX+337,032 shares · +51%
  6. Xencor Inc. XNCR+377,037 shares · +8%
  7. Rezolute Inc. RZLT+265,039 shares · +3%
  8. Zai Lab Limited ZLAB+36,271 shares · +1%

and 1 more in the table below

Trimmed 10

  1. Nuvalent Inc. NUVL-1.3 million shares · -51%
  2. Edgewise Therapeutics Inc. EWTX-2.0 million shares · -20%
  3. Vor Biopharma Inc. VOR-3.0 million shares · -56%
  4. Geron Corp. GERN-21.0 million shares · -33%
  5. Aktis Oncology Inc. AKTS-188,679 shares · -13%
  6. Adicet Bio Inc. ACET-250,000 shares · -21%
  7. Werewolf Therapeutics Inc. HOWL-4.3 million shares · -64%
  8. GH Research PLC GHRS-39,884 shares · -1%

and 2 more in the table below

Sold out of 18

  1. Ascendis Pharma A/s ASND$2.35 billion last quarter
  2. Dianthus Therapeutics Inc. DNTH$219.2 million last quarter
  3. Praxis Precision Medicines I PRAX$120.4 million last quarter
  4. Sarepta Therapeutics, Inc. SRPT$84.9 million last quarter
  5. Spyre Therapeutics Inc. SYRE$81.8 million last quarter
  6. Fulcrum Therapeutics Inc. FULC$46.4 million last quarter
  7. Olema Pharmaceuticals Inc. OLMA$38.8 million last quarter
  8. Design Therapeutics Inc. DSGN$31.6 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Ascendis Pharma A/s ASND10,281,496$2.74 billion23.83%new
Parabilis Medicines Inc. Com PBLS28,933,371$791.9 million6.88%new
Rhythm Pharmaceuticals Inc. RYTM6,666,837$740.2 million6.43%no change
Vaxcyte Inc. PCVX11,474,599$667.0 million5.80%no change
Sionna Therapeutics Inc SION9,905,045$435.7 million3.79%no change
Tyra Biosciences Inc. TYRA12,198,625$389.6 million3.39%no change
Edgewise Therapeutics Inc. EWTX8,392,730$341.0 million2.96%-2,035,707
Newamsterdam Pharma Company NAMS9,550,191$323.7 million2.81%no change
Hemab Therapeutics Hldgs Inc. COAG7,808,627$286.8 million2.49%new
Septerna Inc. SEPN6,995,858$234.3 million2.04%no change
Bicara Therapeutics Inc. BCAX7,255,993$215.4 million1.87%no change
Mineralys Therapeutics Inc. MLYS7,692,750$207.6 million1.80%no change
GH Research PLC GHRS7,636,813$205.3 million1.78%-39,884
Disc Medicine Inc. IRON2,450,221$179.2 million1.56%no change
Spyglass Pharma Inc. SGP8,021,117$178.6 million1.55%no change
Artiva Biotherapeutics Inc. ARTV17,955,642$174.2 million1.51%+8,102,340
Janux Therapeutics Inc. JANX11,189,693$171.9 million1.49%no change
Taysha Gene Therapies Inc. TSHA23,555,648$160.4 million1.39%no change
Biocryst Pharmaceuticals Inc. BCRX15,827,186$158.3 million1.38%no change
Wave Life Sciences Ltd WVE26,975,505$156.7 million1.36%no change
Nuvalent Inc. NUVL1,246,456$153.9 million1.34%-1,287,689
Abivax SA ABVX1,132,557$150.9 million1.31%new
Oruka Therapeutics Inc. ORKA1,554,597$148.0 million1.29%new
Eliem Therapeutics Inc. CLYM11,300,939$147.4 million1.28%no change
Solid Biosciences Inc. SLDB12,036,126$120.2 million1.04%+2,696,148
Zai Lab Limited ZLAB5,743,533$109.1 million0.95%+36,271
Ars Pharmaceuticals Inc. SPRY10,860,977$87.0 million0.76%no change
Xencor Inc. XNCR5,274,274$84.9 million0.74%+377,037
Jade Biosciences Inc. JBIO3,671,083$81.6 million0.71%no change
Intellia Therapeutics Inc. NTLA4,526,926$76.6 million0.67%new
LB Pharmaceuticals Inc. LBRX2,208,604$71.7 million0.62%no change
Definium Therapeutics Inc. DFTX1,500,000$70.6 million0.61%new
Aclaris Therapeutics Inc. ACRS12,723,026$67.3 million0.58%+5,918,954
4D Molecular Therapeutics in FDMT5,049,779$67.2 million0.58%no change
Sana Biotechnology Inc. SANA18,750,000$65.4 million0.57%new
Galecto Inc. DMRA2,399,702$62.4 million0.54%+392
Monopar Therapeutics Inc. MNPR667,207$61.8 million0.54%no change
Acumen Pharmaceuticals Inc. ABOS20,992,669$56.1 million0.49%no change
Geron Corp. GERN42,809,751$54.8 million0.48%-20,961,615
Rezolute Inc. RZLT9,445,039$49.1 million0.43%+265,039
Evommune Inc. EVMN3,494,638$46.4 million0.40%no change
Vor Biopharma Inc. VOR2,402,095$44.2 million0.38%-3,002,903
Century Therapeutics Inc. IPSC17,754,430$43.5 million0.38%no change
Aktis Oncology Inc. AKTS1,314,405$42.4 million0.37%-188,679
Bioage Labs Inc. BIOA1,671,648$41.0 million0.36%+21,000
C4 Therapeutics Inc. CCCC8,000,000$37.4 million0.32%no change
Mirum Pharmaceuticals Inc. MIRM318,554$37.3 million0.32%no change
Capricor Therapeutics Inc. CAPR1,507,844$36.3 million0.32%no change
Pepgen Inc. PEPG20,064,545$36.1 million0.31%no change
Prelude Therapeutics Inc. PRLD6,475,882$34.5 million0.30%new
Nkarta Inc. NKTX10,805,129$30.6 million0.27%no change
Q32 Bio Inc. QTTB2,332,457$29.7 million0.26%new
Anteris Technologies Global AVR3,000,000$29.6 million0.26%no change
Editas Medicine, Inc. EDIT8,889,000$28.8 million0.25%new
Ovid Therapeutics Inc. OVID10,500,968$28.2 million0.25%-213,032
Assembly Biosciences Inc. ASMB1,020,410$28.0 million0.24%no change
Alx Oncology Holdings Inc. ALXO13,011,849$26.9 million0.23%no change
Benitec Biopharma Inc. BNTC1,850,000$24.8 million0.22%no change
Lenz Therapeutics Inc. LENZ4,178,823$23.7 million0.21%no change
Lexeo Therapeutics Inc. LXEO5,000,000$23.3 million0.20%no change
Acrivon Therapeutics Inc. ACRV12,229,396$21.8 million0.19%+3,888,888
Altimmune, Inc. (alt) ALT6,500,000$19.8 million0.17%new
Karyopharm Therapeutics Inc. KPTI1,917,354$18.7 million0.16%no change
Bright Minds Biosciences Inc. DRUG265,000$18.6 million0.16%no change
Avalo Therapeutics Inc. AVTX1,000,000$18.5 million0.16%+337,032
Onkure Therapeutics Inc OKUR3,998,333$18.2 million0.16%no change
Sensei Biotherapeutics Inc. FTH722,020$18.1 million0.16%new
Aura Biosciences Inc. AURA2,500,000$17.8 million0.15%new
Sab Biotherapeutics Inc. SABS4,401,500$17.2 million0.15%no change
Seaport Therapeutics Inc. SPTX700,000$15.2 million0.13%new
Palisade Bio Inc. PALI7,124,116$14.9 million0.13%no change
Helix Acquisition Corp. III HLXC1,250,000$13.3 million0.12%no change
Waystar Holding Corp. WAY529,400$10.9 million0.09%no change
Equillium Inc. EQ3,096,336$9.9 million0.09%no change
Macrogenics Inc. MGNX1,864,176$8.6 million0.07%no change
Perceptive Cap Solutions Cor PCSC750,000$8.2 million0.07%no change
Adicet Bio Inc. ACET932,624$8.1 million0.07%-250,000
Newamsterdam Pharma Company333,333$7.1 million0.06%no change
Corvus Pharmaceuticals Inc. CRVS450,000$6.7 million0.06%no change
Rani Therapeutics Holdings-A RANI8,500,000$6.5 million0.06%no change
Jatt II Acquisition Corp. JATT500,000$5.7 million0.05%new
Amanat Acquisition Corp. AMAN375,000$3.8 million0.03%new
Werewolf Therapeutics Inc. HOWL2,387,744$859,3490.01%-4,293,563
Palatin Technologies Inc. PTNT62,124$670,3180.01%-7,876
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 18 it sold out of are in the box above.